Correction of genetic errors, commonly known as gene editing, holds promise to treat diseases with unmet medical needs. However, gene therapy trials do encounter unwanted outcomes, because of an incomplete understanding of the disease states, and gene therapy processes, among others. This situation encourages a concept that healthcare professionals receiving laboratory research training will not only identify inadequacies in basic biomedical knowledge of gene therapies but also provide tangible refinements. To this end, we have undertaken the PharmD student training in gene editing in a basic research laboratory setting. As a model, MYC gene was chosen for knockout using CRISPR-Cas9 method in HT29 and OVCAR8 cells. Students were involved in the design of MYC -specific gRNAs, subcloning into Cas9-carrying plasmid, and selection of knockout clones from the transfected cells. Subsequently, genomic DNA isolation and sequencing, analysis of clonal DNA sequences using online bioinformatics tools, western blotting, cell proliferation and cell division cycle experiments, were performed to characterize the MYC knockout clones. Results presented in this communication suggest that healthcare professionals who received laboratory training gain a better understanding of the disease states and mechanisms, gene therapy protocols, limitations of gene therapies, ability to critically evaluate the literature and confidence in the oversight of gene therapies in the clinic.
Ahmed, Z., Zeeshan, S., Mendhe, D. and Dong, X. (2020) Human Gene and Disease Associations for Clinical-Genomics and Precision Medicine Research. Clinical and Translational Medicine, 10, 297-318. https://doi.org/10.1002/ctm2.28
Stenson, P.D., Mort, M., Ball, E.V., Evans, K., Hayden, M., Heywood, S., et al. (2017) The Human Gene Mutation Database: Towards a Comprehensive Repository of Inherited Mutation Data for Medical Research, Genetic Diagnosis and Next-Generation Sequencing Studies. Human Genetics, 136, 665-677. https://doi.org/10.1007/s00439-017-1779-6
Dunbar, C.E., High, K.A., Joung, J.K., Kohn, D.B., Ozawa, K. and Sadelain, M. (2018) Gene Therapy Comes of Age. Science, 359, eaan4672. https://doi.org/10.1126/science.aan4672
Chandrasegaran, S. and Carroll, D. (2016) Origins of Programmable Nucleases for Genome Engineering. Journal of Molecular Biology, 428, 963-989. https://doi.org/10.1016/j.jmb.2015.10.014
Zhang, H., Cheng, Q.X., Liu, A.M., Zhao, G.P. and Wang, J. (2017) A Novel and Efficient Method for Bacteria Genome Editing Employing both CRISPR/Cas9 and an Antibiotic Resistance Cassette. Frontiers in Microbiology, 8, Article No. 812. https://doi.org/10.3389/fmicb.2017.00812
Hampton, T. (2020) With First CRISPR Trials, Gene Editing Moves toward the Clinic. JAMA, 323, 1537-1539. https://doi.org/10.1001/jama.2020.3438
Kan, M.J. and Doudna, J.A. (2022) Treatment of Genetic Diseases with CRISPR Genome Editing. JAMA, 328, 980-981. https://doi.org/10.1001/jama.2022.13468
Wang, J.Y. and Doudna, J.A. (2023) CRISPR Technology: A Decade of Genome Editing Is Only the Beginning. Science, 379, eadd8643. https://doi.org/10.1126/science.add8643
Kratzer, K., Getz, L.J., Peterlini, T., Masson, J.Y. and Dellaire, G. (2022) Addressing the Dark Matter of Gene Therapy: Technical and Ethical Barriers to Clinical Application. Human Genetics, 141, 1175-1193. https://doi.org/10.1007/s00439-021-02272-5
Pieczynski, J.N., Deets, A., McDuffee, A. and Lynn Kee, H. (2019) An Undergraduate Laboratory Experience Using CRISPR-cas9 Technology to Deactivate Green Fluorescent Protein Expression in Escherichia coli. Biochemistry and Molecular Biology Education, 47, 145-155. https://doi.org/10.1002/bmb.21206
Satelli, A., Rao, P.S., Thirumala, S. and Rao, U.S. (2011) Galectin-4 Functions as a Tumor Suppressor of Human Colorectal Cancer. International Journal of Cancer, 129, 799-809. https://doi.org/10.1002/ijc.25750
Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A. and Zhang, F. (2013) Genome Engineering Using the CRISPR-Cas9 System. Nature Protocols, 8, 2281-2308, Nov. https://doi.org/10.1038/nprot.2013.143
Vistica, D.T., Skehan, P., Scudiero, D., Monks, A., Pittman, A. and Boyd, M.R. (1991) Tetrazolium-Based Assays for Cellular Viability: A Critical Examination of Selected Parameters Affecting Formazan Production. Cancer Research, 51, 2515-2520.
Rao, P.S. and Rao, U.S. (2021) Statins Decrease the Expression of c-Myc Protein in Cancer Cell Lines. Molecular and Cellular Biochemistry, 476, 743-755. https://doi.org/10.1007/s11010-020-03940-2
Satelli, A., Rao, P.S., Gupta, P.K., Lockman, P.R., Srivenugopal, K.S. and Rao, U.S. (2008) Varied Expression and Localization of Multiple Galectins in Different Cancer Cell Lines. Oncology Reports, 19, 587-594. https://doi.org/10.3892/or.19.3.587
Rao, U.S. and Rao, P.S. (2017) Surface-Bound Galectin-4 Regulates Gene Transcription and Secretion of Chemokines in Human Colorectal Cancer Cell Lines. Tumor Biology, 39, 1-11. https://doi.org/10.1177/1010428317691687
Alitalo, K., Schwab, M., Lin, C.C., Varmus, H.E. and Bishop, J.M. (1983) Homogeneously Staining Chromosomal Regions Contain Amplified Copies of an Abundantly Expressed Cellular Oncogene (c-myc) in Malignant Neuroendocrine Cells from a Human Colon Carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 80, 1707-1711. https://doi.org/10.1073/pnas.80.6.1707
Gabay, M., Li, Y. and Felsher, D.W. (2014) MYC Activation Is a Hallmark of Cancer Initiation and Maintenance. Cold Spring Harbor Perspectives in Medicine, 4, a014241. https://doi.org/10.1101/cshperspect.a014241
Gartel, A.L., Ye, X., Goufman, E., Shianov, P., Hay, N., Najmabadi, F., et al. (2001) Myc Represses the p21(WAF1/CIP1) Promoter and Interacts with Sp1/Sp3. Proceedings of the National Academy of Sciences of the United States of America, 98, 4510-4515. https://doi.org/10.1073/pnas.081074898
Putman, L. (1998) Debate Grows on Safety of Gene-Therapy Vectors. The Lancet, 351, 808. https://doi.org/10.1016/S0140-6736(05)78938-8
Shirley, J.L., de Jong, Y.P., Terhorst, C. and Herzog, R.W. (2020) Immune Responses to Viral Gene Therapy Vectors. Molecular Therapy, 28, 709-722. https://doi.org/10.1016/j.ymthe.2020.01.001
Kelley, W.N. (2012) A Personal Perspective on the Early, Early History of in Vivo (DNA-Based) Gene Therapy. Human Gene Therapy, 23, 541-546. https://doi.org/10.1089/hum.2012.028
Wirth, T., Parker, N. and Yla-Herttuala, S. (2013) History of Gene Therapy. Gene, 525, 162-169. https://doi.org/10.1016/j.gene.2013.03.137
Uddin, F., Rudin, C.M. and Sen, T. (2020) CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future. Frontiers in Oncology, 10, Article No. 1387. https://doi.org/10.3389/fonc.2020.01387
Somia, N. and Verma, I.M. (2000) Gene Therapy: Trials and Tribulations. Nature Reviews Genetics, 1, 91-99. https://doi.org/10.1038/35038533
Rao, P.S., Labhart, M., Mayhew, S.L., Thirumala, S. and Rao, U.S. (2014) Heterogeneity in the Expression of Receptors in the Human Breast Cancer Metastasized to the Brain. Tumor Biology, 35, 7267-7273. https://doi.org/10.1007/s13277-014-1979-9
Rao, U.S., Hoerster, N.S., Thirumala, S. and Rao, P.S. (2013) The Influence of Metastatic Site on the Expression of CEA and Cellular Localization of Beta-Catenin in Colorectal Cancer. Journal of Gastroenterology and Hepatology, 28, 505-512. https://doi.org/10.1111/jgh.12083
Rao, P.S., Endicott, R., Mullins, R. and Rao, U.S. (2018) A 6-Week Laboratory Research Rotation in Pharmacogenomics: A Model for Preparing Pharmacy Students to Practice Precision Medicine. The Pharmacogenomics Journal, 18, 601-608. https://doi.org/10.1038/s41397-018-0019-3
Ruan, W. and Lai, M. (2007) Actin, a Reliable Marker of Internal Control? Clinica Chimica Acta, 385, 1-5. https://doi.org/10.1016/j.cca.2007.07.003
Kawai, K., Viars, C., Arden, K., Tarin, D., Urquidi, V. and Goodison, S. (2002) Comprehensive Karyotyping of the HT-29 Colon Adenocarcinoma Cell Line. Genes Chromosomes Cancer, 34, 1-8. https://doi.org/10.1002/gcc.10003
Roschke, A.V., Stover, K., Tonon, G., Schaffer, A.A. and Kirsch, I.R. (2002) Stable Karyotypes in Epithelial Cancer Cell Lines despite High Rates of Ongoing Structural and Numerical Chromosomal Instability. Neoplasia, 4, 19-31. https://doi.org/10.1038/sj.neo.7900197
Kosicki, M., Tomberg, K. and Bradley, A. (2018) Repair of Double-Strand Breaks Induced by CRISPR-Cas9 Leads to Large Deletions and Complex Rearrangements. Nature Biotechnology, 36, 765-771. https://doi.org/10.1038/nbt.4192
Lalonde, S., Stone, O.A., Lessard, S., Lavertu, A., Desjardins, J., Beaudoin, M., et al. (2017) Frameshift Indels Introduced by Genome Editing Can Lead to In-Frame Exon Skipping. PLOS ONE, 12, e0178700. https://doi.org/10.1371/journal.pone.0178700
Mou, H., Smith, J.L., Peng, L., Yin, H., Moore, J., Zhang, X.O., et al. (2017) CRISPR/Cas9-Mediated Genome Editing Induces Exon Skipping by Alternative Splicing or Exon Deletion. Genome Biology, 18, Article No. 108. https://doi.org/10.1186/s13059-017-1237-8
Rayner, E., Durin, M.A., Thomas, R., Moralli, D., O’Cathail, S.M., Tomlinson, I., et al. (2019) CRISPR-Cas9 Causes Chromosomal Instability and Rearrangements in Cancer Cell Lines, Detectable by Cytogenetic Methods. The CRISPR Journal, 2, 406-416. https://doi.org/10.1089/crispr.2019.0006